We’re proud to share that Digistain® was featured in the Startup Spotlight at Onco:Innovate 2025 as part of ViennaUp, recognised among the leading innovators transforming cancer care.
Dr. Hemmel Amrania presented our Cancer Recurrence Risk Assessment solution to an audience of clinicians, investors, and healthcare stakeholders — highlighting how Digistain® delivers faster, more affordable risk profiling that fits seamlessly into existing clinical workflows, empowering clinicians to personalise treatment decisions and spare patients from unnecessary chemotherapy.
Onco:Innovate 2025 brought together the brightest minds across diagnostics, treatment planning, immunotherapy, and post-treatment care. Being selected as part of this showcase reaffirms our commitment to closing the gap from innovation to patient impact.
